Abecma (idecabtagene vicleucel), First Cell-Based Gene Therapy for Adult Patients with Multiple Myeloma
3 Aprile 2021
The U.S. Food and Drug Administration approved Abecma (idecabtagene vicleucel), a cell-based gene therapy to treat adult patients with multiple myeloma who have not responded
